[go: up one dir, main page]

AR081874A1 - Metodo para predecir eficacia a un regimen terapeutico en un paciente con adenocarcinomas mediante la expresion de un gen reparador de adn (msh3) - Google Patents

Metodo para predecir eficacia a un regimen terapeutico en un paciente con adenocarcinomas mediante la expresion de un gen reparador de adn (msh3)

Info

Publication number
AR081874A1
AR081874A1 ARP110102043A ARP110102043A AR081874A1 AR 081874 A1 AR081874 A1 AR 081874A1 AR P110102043 A ARP110102043 A AR P110102043A AR P110102043 A ARP110102043 A AR P110102043A AR 081874 A1 AR081874 A1 AR 081874A1
Authority
AR
Argentina
Prior art keywords
patient
msh3
expression
cells
genotoxic
Prior art date
Application number
ARP110102043A
Other languages
English (en)
Inventor
Minoru Koi
Ajay Goel
C Richard Boland
Masanobu Takahashi
Original Assignee
Baylor Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Res Inst filed Critical Baylor Res Inst
Publication of AR081874A1 publication Critical patent/AR081874A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G01N33/57535—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cell Biology (AREA)

Abstract

Métodos para tratar un paciente que se halla en riesgo de contraer cáncer colorrectal o al que se le ha diagnosticado cáncer colorrectal. El método de la presente permite determinar la expresión general de MSH3 en células sospechadas de ser células de cáncer colorrectal del paciente y predecir la eficacia potencial de una terapia con un agente anti-neoplásico genotóxico en el tratamiento del paciente, donde una disminución en la expresión general de MSH3 en las células del paciente, en comparación con la expresión de MSH3 en las células colorrectales normales, es indicativa de una predisposición a la respuesta a la terapia con el agente antineoplásico genotóxico, donde la terapia comprende administrarles una cantidad eficaz del agente antineoplásico genotóxico a los pacientes, tal como inhibidores de la poli(adenosina-difosfato-ribosa)polimerasa o PARP y drogas de platino.
ARP110102043A 2011-02-12 2011-06-10 Metodo para predecir eficacia a un regimen terapeutico en un paciente con adenocarcinomas mediante la expresion de un gen reparador de adn (msh3) AR081874A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161442192P 2011-02-12 2011-02-12

Publications (1)

Publication Number Publication Date
AR081874A1 true AR081874A1 (es) 2012-10-24

Family

ID=46621117

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110102043A AR081874A1 (es) 2011-02-12 2011-06-10 Metodo para predecir eficacia a un regimen terapeutico en un paciente con adenocarcinomas mediante la expresion de un gen reparador de adn (msh3)

Country Status (9)

Country Link
US (1) US20120207856A1 (es)
JP (1) JP2012165736A (es)
KR (1) KR20120093049A (es)
CN (1) CN102636648A (es)
AR (1) AR081874A1 (es)
AU (1) AU2011202823C1 (es)
BR (1) BRPI1103285A2 (es)
CA (1) CA2742342A1 (es)
MX (1) MX2011008748A (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104885090A (zh) 2012-10-09 2015-09-02 凡弗3基因组有限公司 肿瘤克隆性分析的系统和方法
LT2920168T (lt) 2012-11-16 2021-10-25 Calithera Biosciences, Inc. Heterociklinis gliutaminazės inhibitorius
WO2014164730A2 (en) * 2013-03-12 2014-10-09 The Board Of Trustees Of The Leland Stanford Junior University Modulation of cellular dna repair activity to intercept malignancy
EP3543353A1 (en) * 2013-09-23 2019-09-25 The University of Chicago Methods and compositions relating to cancer therapy with dna damaging agents
CN107027291B (zh) * 2014-06-13 2020-10-30 卡利泰拉生物科技公司 用谷氨酰胺酶抑制剂的组合疗法
EP3174984B1 (en) * 2014-07-31 2020-05-06 Academia Sinica Antagonistic ctla-4 aptamers and applications thereof in enhancing immune activity
SG11201700816YA (en) 2014-08-07 2017-02-27 Calithera Biosciences Inc Crystal forms of glutaminase inhibitors
CN104887680A (zh) * 2015-05-08 2015-09-09 胡继承 多聚adp核糖聚合酶抑制剂治疗乙肝病毒相关疾病的新用途
WO2017013237A1 (en) 2015-07-23 2017-01-26 Institut Curie Use of a combination of dbait molecule and parp inhibitors to treat cancer
CN108601767A (zh) 2015-10-05 2018-09-28 卡利泰拉生物科技公司 用谷氨酰胺酶抑制剂和免疫肿瘤学药剂的组合疗法
CA3004504A1 (en) 2015-11-06 2017-05-11 Ventana Medical Systems, Inc. Tissue homogenisation for representative diagnostics
EP3214222B1 (de) 2016-03-02 2018-05-09 Joseph Vögele AG Einbaubohlenbaugruppe und verfahren zum betrieb deren
HUE064978T2 (hu) 2016-06-29 2024-04-28 Tesaro Inc A petefészekrák kezelésének módszerei
MX2019013373A (es) 2017-05-09 2020-08-03 Tesaro Inc Terapias de combinación para tratar cáncer.
MA49144A (fr) 2017-05-18 2020-03-25 Tesaro Inc Polythérapies pour le traitement du cancer
WO2019067978A1 (en) 2017-09-30 2019-04-04 Tesaro, Inc. POLYTHERAPIES FOR THE TREATMENT OF CANCER
EP3691685A1 (en) 2017-10-06 2020-08-12 Tesaro Inc. Combination therapies and uses thereof
EP3502700A1 (en) * 2017-12-21 2019-06-26 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Methods based on the detection of rad51 foci in tumor cells
BR112020013214A2 (pt) * 2017-12-27 2020-12-01 Tesaro, Inc. métodos para tratar um câncer
WO2021037978A1 (en) * 2019-08-28 2021-03-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of cancer
WO2022098086A1 (ko) * 2020-11-04 2022-05-12 한국과학기술원 비기능성 전사체를 이용한 parp 저해제 또는 dna 손상 약물 감수성 판정방법
CN113667750B (zh) * 2021-08-11 2022-05-17 广州市番禺区中心医院(广州市番禺区人民医院、广州市番禺区心血管疾病研究所) 一种用于结直肠癌诊断的circRNA标志物的应用
CN118615452A (zh) * 2023-03-07 2024-09-10 中国科学院分子细胞科学卓越创新中心 Dna损伤药物联合化疗
WO2025183523A1 (ko) * 2024-02-29 2025-09-04 아주대학교 산학협력단 Parp 억제제 감수성 증가 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2163650T3 (en) * 2004-04-09 2015-11-02 Genomic Health Inc Genekspressionsmarkører for prediction of response to chemotherapy
CN101238373A (zh) * 2005-08-19 2008-08-06 因迪维姆德有限公司 内质蛋白片段及其衍生物作为结肠直肠腺瘤和/或癌的生物标记的用途；用于检测的方法和测试系统
EP2092083A2 (en) * 2006-10-20 2009-08-26 Dana-Farber Cancer Institute Dna damage repair inhibitors and methods for treating cancer
US7618992B2 (en) * 2006-12-29 2009-11-17 Astellas Pharma Inc. Method of treating cancer by co-administration of anticancer agents
WO2009114836A1 (en) * 2008-03-14 2009-09-17 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy

Also Published As

Publication number Publication date
AU2011202823B2 (en) 2012-12-13
CA2742342A1 (en) 2012-08-12
KR20120093049A (ko) 2012-08-22
JP2012165736A (ja) 2012-09-06
CN102636648A (zh) 2012-08-15
AU2011202823A1 (en) 2012-08-30
US20120207856A1 (en) 2012-08-16
BRPI1103285A2 (pt) 2013-11-05
MX2011008748A (es) 2012-08-31
AU2011202823C1 (en) 2013-05-16

Similar Documents

Publication Publication Date Title
AR081874A1 (es) Metodo para predecir eficacia a un regimen terapeutico en un paciente con adenocarcinomas mediante la expresion de un gen reparador de adn (msh3)
Lozada-Delgado et al. RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials
CY1123110T1 (el) Συνδυασμοι και τροποι χορηγησης θεραπευτικων παραγοντων και θεραπεια συνδυασμου
MX2025002382A (es) Anticuerpos antagonistas anti-tigit y anti-pd-l1 y usos de los mismos para el tratamiento del cancer
MY180365A (en) Markers of tumor cell response to anti-cancer therapy
MX2018003028A (es) Reduccion de los niveles o de la actividad de los linfocitos t reguladores sistemicos para el tratamiento de enfermedades y lesiones del sistema nervioso central (snc).
BR112015007144A2 (pt) uso de masitinib para o tratamento de câncer em subpopulações de paciente identificadas usando fatores prognosticadores
BR112017011536A2 (pt) terapias de combinação
CO6561786A2 (es) Terapia combinada para el tratamiento del cancer y ensayos de diagnostico relacionados
AR060306A1 (es) Terapia de combinacion de anticuerpos contra ctla4
CY1123043T1 (el) Συνδυαστικες θεραπειες για την αγωγη ανθεκτικων στη χημειοθεραπεια καρκινων
WO2014205555A8 (en) Methods and uses for diagnosis and treatment of prostate cancer
MX386251B (es) Novedosos fármacos de alta penetración y sus composiciones para el tratamiento de enfermedades de parkinson.
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
MX2019003134A (es) Terapia de combinacion.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112012030641B8 (pt) Usos e composições para terapia farmacêutica oral
CL2023003003A1 (es) Tratamiento y diagnóstico de trastornos inflamatorios
CO2020008863A2 (es) Biomarcadores de tolerancia inmunitaria inducida por metotrexato
MX2018013873A (es) Irinotecan nanoliposomico para usarse en el tratamiento del cancer de pulmon de celulas pequeñas.
BR112012026224A2 (pt) métodos para tratar mal de alzheimer e para avaliar a eficácia de uma terapia
Klein et al. Improvement in peripheral blood disease burden in patients with Sézary syndrome and leukemic mycosis fungoides after total skin electron beam therapy
Teng et al. Evaluating laser photobiomodulation for chemotherapy-induced peripheral neuropathy: a randomised phase II trial
Teoh et al. Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells
Yang et al. Enhanced antitumor effects of radiotherapy combined local nimustine delivery rendezvousing with oral temozolomide chemotherapy in glioblastoma patients

Legal Events

Date Code Title Description
FB Suspension of granting procedure